Gut health breakthrough? probiotic shows promise for heart failure
NCT ID NCT05752760
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether taking a probiotic called Lactobacillus plantarum 299v for 12 weeks could improve exercise ability and blood vessel function in people with heart failure. Ten participants took either the probiotic or a placebo. The goal was to see if the probiotic could reduce inflammation and help the heart and blood vessels work better.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Lactobacillus plantarum 299v probiotic
- What this could lead to
- If it works, this could point toward a simple probiotic supplement to help heart failure patients exercise better and feel better.
- What could go wrong
- This is a very small, early study with only 10 participants. Results may not apply to everyone, and the benefit may be small or absent.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
10 people
The number who actually took part.
- Started
-
Feb 2023
- Finished
-
Mar 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
21 to 89 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age between 21-89 years old * Clinical diagnosis of Congestive Heart Failure (CHF) in the six months prior to enrollment along with an echocardiogram documenting systolic dysfunction with ejection fraction ≤40% * Clinical diagnosis of CHF in the six months prior to enrollment along with an echocardiogram documenting diastolic dysfunction with an ejection fraction ≥50%, and a H2FpEFF score of ≥6 * New York Heart Association (NYHA) Class II-IIID heart failure symptoms with either ischemic or non-ischemic etiology OR similar diagnosis with congestive heart failure (CHF) along with an echocardiogram documenting an LV ejection fraction of 50% or more with similar NYHA classification as those with LVEF of 40% or less * Evidence of systemic inflammation at baseline (C-reactive protein ≥ 2 mg/L at the time of screening) Exclusion Criteria: * Heart failure due to severe valve disease such as Aortic Stenosis, Mitral Regurgitation, or Mitral Stenosis * Cancer besides non-melanoma skin carcinomas or localized prostate and breast cancer at the time of enrollment with life expectancy \<1 year * Lung disease such as Chronic Obstructive Pulmonary Disease (COPD), emphysema, or Pulmonary fibrosis * Active inflammatory disease or infectious disease at the time of enrollment * Current treatment (or use within the past 14 days) of steroids or anti-inflammatory treatments (excluding non-steroidal anti-inflammatory medications or steroids used solely for IV contrast dye allergy) * Chronic Kidney Disease with eGFR ≤ 30 mL/min * Hepatic Failure (Child's Class B or C) * Patients with Gastrointestinal (GI) tract illness such as short gut syndrome, inflammatory bowel disease, or an ileostomy, such that probiotic absorption would be altered * Anticipated need for cardiac surgery during the projected study period for the subject * Pregnancy * Patients who are receiving Vitamin K antagonists such as Coumadin or Warfarin * Neutropenia (Absolute Neutrophil Count (ANC) \< 1800/mm3) * Inability to give informed consent or follow the study protocol * On antibiotics at the time of enrollment or within one month of enrollment * Currently taking a Lactobacillus based probiotic as an outpatient at the time of enrollment * Patients who are unable to walk on treadmill or use a bicycle to participate in exercise testing * Allergy to Lp299v probiotic supplement
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Heart failure are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can biomarkers predict which elderly heart failure patients will return to hospital?
- Can a daily pill shield hearts in HFpEF?
- Can an inhaler boost heart pumping in COPD patients?
- Can zapping the heart beat drugs for AF in heart failure?
- Could a handheld ultrasound help clinics spot heart failure sooner?
- Which SGLT2 inhibitor wins? trial pits empagliflozin against dapagliflozin